2-(cyclopentylamino)-6-fluoro-4-(3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indazol-1-yl)benzamide | 1073969-59-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-(cyclopentylamino)-6-fluoro-4-(3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indazol-1-yl)benzamide
• 英文别名: 2-(cyclopentylamino)-6-fluoro-4-(3,6,6-trimethyl-4-oxo-5,7-dihydroindazol-1-yl)benzamide
• CAS: 1073969-59-1
• 化学式: C₂₂H₂₇FN₄O₂
• 分子量: 398.48
• InChiKey: GVODDAFCWKAGSZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  29
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  90
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  2-(cyclopentylamino)-6-fluoro-4-(3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indazol-1-yl)benzonitrile 在 sodium hydroxide 、 水 、 双氧水 作用下， 以 乙醇 、 二甲基亚砜 为溶剂， 以20%的产率得到2-(cyclopentylamino)-6-fluoro-4-(3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indazol-1-yl)benzamide
  参考文献：
  名称：

  Tetrahydroindole and Tetrahydroindazole Derivatives

  摘要：

  该发明提供了式（I）的吲哚和吲唑化合物，或其药学上可接受的盐，用于治疗和/或预防通过抑制热休克蛋白90改善的疾病和/或紊乱。该发明还提供了包含式（I）化合物的药物组合物以及制备式（I）化合物的方法。

  公开号：

  US20080269193A1

文献信息

• TARGETED THERAPEUTICS
  申请人：Synta Pharmaceuticals Corp.

  公开号：US20150139905A1

  公开（公告）日：2015-05-21

  The present invention provides pharmacological compounds including an effector moiety conjugated to a binding moiety that directs the effector moiety to a biological target of interest. Likewise, the present invention provides compositions, kits, and methods (e.g., therapeutic, diagnostic, and imaging) including the compounds. The compounds can be described as a protein interacting binding moiety-drug conjugate (SDC-TRAP) compounds, which include a protein interacting binding moiety and an effector moiety. For example, in certain embodiments directed to treating cancer, the SDC-TRAP can include an Hsp90 inhibitor conjugated to a cytotoxic agent as the effector moiety.

  本发明提供了药理化合物，包括结合基团共轭到效应基团，以将效应基团定向到感兴趣的生物靶点。同样，本发明提供了包括这些化合物的组合物、试剂盒和方法（例如治疗、诊断和成像）。这些化合物可以被描述为蛋白质相互作用结合基团-药物共轭（SDC-TRAP）化合物，其中包括蛋白质相互作用结合基团和效应基团。例如，在某些治疗癌症的实施例中，SDC-TRAP可以包括Hsp90抑制剂共轭到细胞毒素作为效应基团。
• TETRAHYDROINDOLE AND TETRAHYDROINDAZOLE DERIVATIVES
  申请人：Serenex, Inc.

  公开号：EP2146967A2

  公开（公告）日：2010-01-27
• USE OF TETRAHYDROINDAZOLYLBENZAMIDE AND TETRAHYDROINDOLYLBENZAMIDE DERIVATIVES FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) AND ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS)
  申请人：Esanex, Inc.

  公开号：US20160143884A1

  公开（公告）日：2016-05-26

  Provided are methods of treating or inhibiting Human Immunodeficiency Virus (HIV) infection, or treating or inhibiting Acquired Human Immunodeficiency Syndrome (AIDS) in a subject in need thereof, comprising administering an Hsp90 inhibitor in a therapeutically effective amount.
• [EN] TETRAHYDROINDOLE AND TETRAHYDROINDAZOLE DERIVATIVES<br/>[FR] DÉRIVÉS DE TÉTRAHYDROINDOLE ET DE TÉTRAHYDROINDAZOLE
  申请人：SERENEX INC

  公开号：WO2008130879A2

  公开（公告）日：2008-10-30

  [EN] The invention provides indole and indazole compounds of Formula (I) or pharmaceutically acceptable salts thereof which are useful for treating and/or preventing diseases and/or disorders ameliorated by the inhibition of Heat-Shock Protein 90. The invention further provides pharmaceutical compositions comprising compounds of Formula (I) and methods of preparing compounds of Formula (I).
  [FR] L'invention concerne des composés d'indole et d'indazole de formule (I) ou leurs sels pharmaceutiquement acceptables. Les composés selon l'invention sont utiles pour le traitement et/ou la prévention de maladies et/ou de troubles améliorés par l'inhibition de la protéine Hsp90 (Heat-Shock Protein 90). L'invention concerne également des compositions pharmaceutiques qui comprennent des composés de formule (I) et des procédés de préparation des composés de formule (I).
• Tetrahydroindole and Tetrahydroindazole Derivatives
  申请人：Huang Kenneth He

  公开号：US20080269193A1

  公开（公告）日：2008-10-30

  The invention provides indole and indazole compounds of Formula (I) or pharmaceutically acceptable salts thereof which are useful for treating and/or preventing diseases and/or disorders ameliorated by the inhibition of Heat-Shock Protein 90. The invention further provides pharmaceutical compositions comprising compounds of Formula (I) and methods of preparing compounds of Formula (I).

  该发明提供了式（I）的吲哚和吲唑化合物，或其药学上可接受的盐，用于治疗和/或预防通过抑制热休克蛋白90改善的疾病和/或紊乱。该发明还提供了包含式（I）化合物的药物组合物以及制备式（I）化合物的方法。